Clinical Trial

Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, single-arm, single-dose Phase I/II clinical study. It aims to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of LY-M003 Injection in patients with Wilson's Disease (WD).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-08.
Trial Details
NCT Number NCT07641140
Lead Sponsor Lingyi Biotech Co., Ltd.
Conditions Wilson's Disease
Enrollment 18 participants
Start Date 2026-06-15
Primary Completion 2027-12-30 (estimated)
Study Completion 2032-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-02